Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02877732 · ClinicalTrials.gov registry record · NA

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2

A NA study, sponsored by Stanford University.

Terminated
Registry status
NA
Development phase
12
Enrollment target

NCT02877732: Clinical Trial NA study, sponsored by Stanford University.

NCT02877732 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02877732, a NA study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This is a prospective multi-center cohort feasibility and exploratory study.

Primary Outcome

The EYE-SYNC test will be performed immediately after an impact, 2 days, 7 days and 14 days post impact. The movement of eye will be tracked using EYE-SYNC. The data will be recorded in a surface tablet connected to EYE-SYNC.

Interventions

  • DEVICE EYE-SYNC eye-tracking
  • OTHER SCAT-3 subtests
  • OTHER DEM
  • OTHER Simple Reaction Time subtest of ANAM-SRT
  • OTHER Level of Alertnesss

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-07
Est. Completion 2017-04
Phase NA
Stanford University

1,744 total trials

Why NCT02877732 stopped before completion

NCT02877732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 5 interventions - of which EYE-SYNC eye-tracking is the first listed.

NCT02877732 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02877732 about?

NCT02877732 is a clinical study titled "EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2". This is a prospective multi-center cohort feasibility and exploratory study.

What is the current status of trial NCT02877732?

This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2016-07. Estimated completion is 2017-04.

What interventions are being tested in trial NCT02877732?

The interventions under investigation include: EYE-SYNC eye-tracking (DEVICE), SCAT-3 subtests (OTHER), DEM (OTHER), Simple Reaction Time subtest of ANAM-SRT (OTHER), Level of Alertnesss (OTHER).

Who is sponsoring clinical trial NCT02877732?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02877732's enrollment target sits among peer trials

12 1913th of 2000 higher than 74 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02877732, the US trial registry maintained by the National Library of Medicine. NCT02877732 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.